Yoshiharu Reports Third Quarter 2024 Financial Results
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron’s $256M 23andMe Acquisition
Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor SamplesPITTSBURGH, May...